Cadrenal Therapeutics, Inc. Common Stock
CVKD · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| % Growth | – | – | – |
| Cost of Goods Sold | $0 | $0 | $1 |
| Gross Profit | $0 | $0 | -$1 |
| % Margin | – | – | – |
| R&D Expenses | $4,205 | $4,081 | $393 |
| G&A Expenses | $6,754 | $3,550 | $0 |
| SG&A Expenses | $6,754 | $3,550 | $2,308 |
| Sales & Mktg Exp. | $0 | $0 | $0 |
| Other Operating Expenses | $2 | $2 | $0 |
| Operating Expenses | $10,961 | $7,633 | $2,700 |
| Operating Income | -$10,961 | -$7,633 | -$2,702 |
| % Margin | – | – | – |
| Other Income/Exp. Net | $309 | -$724 | -$4,013 |
| Pre-Tax Income | -$10,651 | -$8,357 | -$6,714 |
| Tax Expense | $0 | $0 | $0 |
| Net Income | -$10,651 | -$8,357 | -$6,714 |
| % Margin | – | – | – |
| EPS | -8.73 | -9.63 | -8.66 |
| % Growth | 9.3% | -11.2% | – |
| EPS Diluted | -8.73 | -9.63 | -8.66 |
| Weighted Avg Shares Out | 1,220 | 868 | 776 |
| Weighted Avg Shares Out Dil | 1,220 | 868 | 776 |
| Supplemental Information | – | – | – |
| Interest Income | $309 | $249 | – |
| Interest Expense | $0 | $17 | $107 |
| Depreciation & Amortization | $2 | $2 | $1 |
| EBITDA | -$10,649 | -$8,338 | -$6,606 |
| % Margin | – | – | – |